Is this share the ASX 200's best healthcare buy?

Could 2023 be Ansell's time to shine?

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX 200 healthcare share Ansell could be a buy right now, according to experts
  • Allan Gray fundies like its defensive qualities and tip it to grow its earnings 
  • Meanwhile, Fairmont Equities is bullish on the stock on a technical basis

Could this embattled S&P/ASX 200 Index (ASX: XJO) healthcare share be a buy right now? Fundies seemingly think so, tipping the glove manufacturer to do big things in the future.

It follows a rough couple of years for the Ansell Limited (ASX: ANN) share price. The stock tumbled 9.4% over 2021 before dumping another 10.4% last year. It currently trades at $28.17.

Created with Highcharts 11.4.3Ansell PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Comparatively, the ASX 200 gained 13% in 2021 and slipped 5.4% over 2022.

So, what has experts talking about the stock in 2023? Let's take a look.

Is this ASX 200 healthcare share a 2023 buy?

Interestingly, while Ansell falls among healthcare shares, it could also be described as an industrial company. That's because it mainly produces gloves and other personal protective equipment.

Perhaps unsurprisingly, then, the company's earnings took off during the COVID-19 pandemic, driving the Ansell share price to a record high in June 2021.

And while its inflated financial year 2021 earnings didn't stick around for financial year 2022, the market reacted positively to news its revenue reached US$1.9 billion last fiscal year, with Macquarie experts reportedly seeing "solid underlying trends".

Indeed, many experts tip the ASX 200 healthcare share's future to be bright. Allan Gray managing director and chief investment officer Simon Mawhinney believes it offers both defensive earnings and good value, saying:

Even though [Ansell] is somewhat exposed to economic cycles, for the most part, they are non-discretionary spends.

[I]mportantly, the share price that you pay today is low relative to earnings. We think you buy a company like Ansell for around 14 times earnings and those earnings, we think, will grow at low single digit percentages.

If you contrast that with the stock market perhaps if we're lucky, a similar growth rate in earnings, but a good 30% or so more expensive.

The ASX 200 healthcare share also looks like a good opportunity on a technical basis, according to Fairmont Equities managing director and founder Michael Gable. He recently flagged the stock as a buy, saying via The Bull:

The share price has been trending higher since June 2022 and breached resistance at $28 in late October. The technical chart remains bullish … the stock is in a strong uptrend, with no signs of weakness.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »